254882-06-9

Basic information

• Product Name: (2S,4R)-N-BOC-4-HYDROXYPIPERIDINE-2-CARBOXYLIC ACID METHYL ESTER, 98% E.E., 95
• Synonyms: (2S,4R)-N-BOC-4-HYDROXYPIPERIDINE-2-CARBOXYLIC ACID METHYL ESTER, 98% E.E., 95;Methyl (2S,4R)-N-BOC-4-hydroxypiperidine-2-carboxylate;(2S,4R)-N-boc-4-Hydroxypiperidine-2-carboxylicacidmethylester(e.e.);(2S,4R)-N-BOC-4-HYDROXYPIPERIDINE-2-CARBO-XYLIC ACID METHYL ESTER 95% (98% E.E.);1-(tert-Butyl) 2-methyl (2S,4R)-4-hydroxypiperidine-1,2-dicarboxylate;Methyl (2S,4R)-4-hydroxypiperidine-2-carboxylate, N-BOC protected 95+%;1,2-Piperidinedicarboxylic acid, 4-hydroxy-, 1-(1,1-diMethylethyl) 2-Methyl ester, (2S,4R)-
• CAS NO: 254882-06-9
• Molecular Formula: C₁₂H₂₁NO₅
• Molecular Weight: 259.29884
• Product Categories: pharmacetical
• Mol File: 254882-06-9.mol

Chemical Properties

• Boiling Point: 402.56°C (rough estimate)
• Flash Point: 166.8°C
• Appearance: /
• Density: 1.182
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.4596 (estimate)
• PKA: 14.39±0.40(Predicted)
• CAS DataBase Reference: (2S,4R)-N-BOC-4-HYDROXYPIPERIDINE-2-CARBOXYLIC ACID METHYL ESTER, 98% E.E., 95(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4R)-N-BOC-4-HYDROXYPIPERIDINE-2-CARBOXYLIC ACID METHYL ESTER, 98% E.E., 95(254882-06-9)
• EPA Substance Registry System: (2S,4R)-N-BOC-4-HYDROXYPIPERIDINE-2-CARBOXYLIC ACID METHYL ESTER, 98% E.E., 95(254882-06-9)

Safety Data

• Safety Statements: S24/25:Avoid contact with skin and eyes.
• RIDADR: UN3077
• Hazardous Substances Data: 254882-06-9(Hazardous Substances Data)

Usage

Chemical Properties

clear colorless viscous liquid

InChI:InChI=1/C12H21NO5/c1-12(2,3)18-11(16)13-6-5-8(14)7-9(13)10(15)17-4/h8-9,14H,5-7H2,1-4H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 211058-80-9 methyl 4(R)-hydroxypiperidine-2(S)-carboxylate 
• 403503-37-7 (2S,4R)-1-benzyl 2-methyl 4-hydroxypiperidine-1,2-dicarboxylate 
• 198646-60-5 (S)-1-(tertbutyloxycarbonyl)-4-oxo-piperidine-2-carboxylic acid 
• 1799811-83-8 1-(tert-butyl)-2-methyl-(S)-4-oxopiperidine-1,2-dicarboxylate 
• 1103929-22-1 methyl (2S,4R)-4-hydroxy-1-((R)-1-phenylethyl)piperidine-2-carboxylate 
• 475504-28-0 4-formyloxy-(S)-pipecolic acid methyl ester 
• 78553-47-6 methyl (2S)-2-[N-(benzyloxycarbonyl)amino]pent-4-enoate 
• 78553-51-2 (S)-2-(benzyloxycarbonylamino)pent-4-enoic acid 
• 50299-14-4 N-Acetyl-α-allylglycine 

Downstream Products

• 908294-09-7 1-tert-butyl 2-methyl (2S,4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)piperidine-1,2-dicarboxylate 
• 1029429-49-9 (2S,4R)-4-hydroxy-2-hydroxymethyl-piperidine-1-carboxylic acid tert-butyl ester 
• 1432130-61-4 C₂₂H₂₉NO₇S₂ 
• 1432130-57-8 C₂₃H₂₉NO₈S₂ 
• 1432130-53-4 C₁₆H₂₃NO₆S 
• 1448668-18-5 C₃₀H₂₉NO₄ 
• 1448668-05-0 C₂₈H₂₉NO₄ 
• 1448668-04-9 (2S,4R)-methyl 1-(2,2-diphenylacetyl)-4-hydroxypiperidine-2-carboxylate 
• 211058-80-9 methyl 4(R)-hydroxypiperidine-2(S)-carboxylate 
• 1448667-65-9 (2S,4S)-4-(benzyloxy)-1-(2,2-diphenylacetyl)piperidine-2-carboxylic acid 
• 1448667-66-0 (2S,4R)-4-(benzyloxy)-1-(2,2-diphenylacetyl)piperidine-2-carboxylic acid 
• 1448668-26-5 C₃₀H₂₈FNO₄ 

Relevant articles and documents

PDD AND BPD COMPOUNDS

The invention relates to pyrridinobenzodiazepines (PDDs) comprising three fused 6-7- 6–membered rings and to benzopyrridodiazecines (BPDs) comprising three fused 6-8- 6–membered rings and, in particular, to PDD or BPD dimers linked together or PDD and BPD monomers linked to aromatic groups, and pharmaceutically acceptable salts thereof, which are useful as medicaments, such as anti-proliferative agents. PDDs and BPDs may be represented by formula (I): and salts or solvates thereof, wherein R2, R4-R6 and R8 are independently selected substituent groups; and either: (i) R9 and R10 together form a double bond; (ii) R9 is H and R10 is OH; or (iii) R9 is H and R10 is ORA and RA is C1-6 alkyl; wherein each of m, n, u and w may be 0 or 1; where (a) the compound is a dimer with each monomer being the same or different and being of formula (I) where one of R1, R2, R3 and R7 of the first monomer and one of R'1, R'2, R3 and R'7 of the second monomer form together a bridge having the formula –X-L-X'- linking the monomers and m + n + u + w = 1; or (b) a dimer and one of R1, R2 and R3 of the first monomer and one of R'1, R'2 and R3 of the second monomer form together a bridge having the formula –X-L-X'- linking the monomers and m = n = u = w = o; or (c) one of R1, R2, R3 and R7 has the formula: –X- L-X'-D or -(CH2)f-O-R14 and m + n + u + w = o or 1; or (d) R7 has the formula: –X-L-X'- D or -(CH2)g-O -15 and m + n + u + w = 1; and X-L-X'- is a linker group and D has the formula (II) or (III):

HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE

The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to piperidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

The discovery of CCR3/H1 dual antagonists with reduced hERG risk

A series of dual CCR3/H1 antagonists based on a bispiperidine scaffold were discovered. Introduction of an acidic group overcame hERG liability. Bioavailability was optimised by modulation of physico-chemical properties and physical form to del

5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS

The invention relates to novel chimeric antibiotics of formula (I) wherein R1 represents OH, OPO3H2 or OCOR5; R2 represents H, OH or OPO3H2; R3 represents H or halogen

Use of hydrolases for the synthesis of cyclic amino acids

The synthesis of several cyclic amino acids that have all the necessary structural features to make them ideal scaffolds for use in medicinal chemistry is described. A key step in each synthesis is the use of hydrolase enzymes to define a chiral centre. I

Chemoenzymatic synthesis of the four diastereoisomers of 4-hydroxypipecolic acid from N-acetyl-(R,S)-allylglycine: Chiral scaffolds for drug discovery

All four diastereoisomers of 4-hydroxypipecolic acid were prepared in a form conveniently protected for drug discovery applications with the use of industrially scaleable methodology. Resolution of the racemic starting material using proprietary acylases followed by an acyliminium ion cyclisation gave diastereomeric mixtures of 4-formyloxypipecolic acid, which were differentiated using an enzyme-catalysed hydrolysis. The products were separated by partition, and by following a sequence of straightforward chemical steps, the individual stereoisomers of the protected 4-hydroxypipecolates were crystallized to optical purity in 100 g quantities.

Synthesis of all isomers of pulcherrimine, a bitter principle in the sea urchin ovary

All eight isomers of pulcherrimine, a bitter principle of the sea urchin (Hemicentrotus pulcherrimus) ovary have been synthesized, which led to revision of the absolute stereochemistry of pulcherrimine. The synthetic pulcherrimine and the 2S isomer were highly bitter at a concentration of 1.0 mM.

Novel constrained CCK-B dipeptoid antagonists derived from pipecolic acid

A new series of 4-substituted pipecolic acid derivatives was prepared and incorporated into dipeptoids. The resulting products behave as moderately potent CCK-B antagonists but their constrained structure and its comparison with structurally related compounds yield valuable information about the conformational requirements for optimal recognition of the CCK-B receptor by antagonists.